2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B

 Supported by Idenix Pharmaceuticals, Inc and Novartis Pharma AG. The corresponding author had full access to all of the data and takes full responsibility for the veracity of the data and analysis. Statistical analyses were performed by the study sponsor and independently by Quartesian, LLC (Princeton, NJ).

 The authors disclose the following: Y.–F.L. was a consultant for Bristol-Myers Squibb, GlaxoSmithKline, and Novartis and has received grant/research support from Bristol–Myers Squibb, Idenix, Novartis, and Gilead. E.G. received consulting fees from Gilead, GlaxoSmithKline, Merck, and Novartis and honoraria from GlaxoSmithKline, Idenix, Novartis, and Roche. N.L. is a speaker for Bristol–Myers Squibb, GlaxoSmithKline, Novartis, and Schering–Plough. S.Z. received consulting fees and/or lecture from Bristol–Myers Squibb, Gilead, GlaxoSmithKline, Novartis, Roche, and Schering–Plough. C.L.L. has received research grants from Idenix-Novartis. E.J.H. served on advisory board for Axcan Pharma, Gilead Sciences, Hoffman-LaRoche, Novartis, Schering-Plough; received research grants/funding from Axcan Pharma, Bristol-Myers-Squibb, Gilead Sciences, GlaxoSmithKline, Hoffman-LaRoche, Idenix, Novartis, Pharmasset, Schering-Plough, Vertex. M.M. received research grants, honoraria, and/or consultancy fees from Bristol–Myers Squibb, Boehringer–Ingelheim, Gilead, Idenix, Novartis, Roche, Schering–Plough, GSK, and Valeant. N.B. has received funding from Roche, Vertex, Schering, Gilead, Pharmasset, Connatus, Idenix, Novartis and speaker bureau fees from Gilead and Novartis. S.–H.H. received grant support, consultancy fees, and lecture fees from Novartis/Idenix. S.G.H. received consulting fees from Bukwang and research grants from Idenix, Valeant, BMS, and GSK. G.P. serves on advisory boards for Bristol–Myers Squibb, Gilead Sciences, Hoffmann–La Roche, Idenix–Novartis, has received research grants (from participation in phase 2/3 trials) from Gilead Sciences and Idenix–Novartis, has received unrestricted research grants from Hoffmann–La Roche, and is a speaker for Bristol–Myers Squibb, Gilead Sciences, Hoffmann–La Roche, and Idenix–Novartis. N.A.B. and K.G. were employees of Idenix at the time of this study. E.A. was an employee of Novartis at the time of the study. N.V.N. is an employee of Novartis. J.N., M.J.T., Y.W., Y. Cakaloglu, and Y. Chen report no conflicts of interest.

PII: S0016-5085(08)01861-1

doi: 10.1053/j.gastro.2008.10.026

© 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.